Bookmark and Share

Active Grant Support

Title: “Neurotoxicity of Organophosphorus Pesticides in Developing Guinea Pigs”

PIs: Edson X. Albuquerque, Rao Gullapalli, Jacek Mamczarz, William Randall
Funding Agency: National Institutes of Health/National Institute of Environmental Health
Funding Period: 7/1/2010 – 6/30/2014

This project will use a multi-disciplinary approach to: (i) identify the structural and functional brain damage induced by the developmental exposure of guinea pigs to the organophosphorus pesticides chlorpyrifos and malathion, (ii) identify potential epigenetic mechanisms underlying the developmental toxicity of these pesticides, and (iii) examine the potential effectiveness of galantamine as an antidotal therapy to treat the neurotoxic effects of the pesticides in the developing guinea pigs.

Title: “Nicotinic Receptor and Hippocampal Synaptic Function”

PI: Edson X. Albuquerque
Funding Agency: National Institutes of Health/National Institute of Neurological Disorders and Stroke
Funding Period: 5/15/08-4/30/13

The aim of this project is to characterize the neuronal nicotinic receptors located in the hippocampal region of the brain, identifying their physiological roles in neuronal function and in synaptic transmission.

Title: “Galantamine and Anticonvulsants in the Treatment of Nerve Agent Toxicity”

PI: Edson X. Albuquerque
Funding Agency: Defense Threat Reduction Agency/Department of Defense
Funding Period: 7/1/2010 – 6/30/2012

This research contract is aimed at determining the effectiveness of a combination of galantamine (or its derivatives) and anticonvulsants to treat convulsions and behavioral impairments caused by the exposure of adult male guinea pigs to the nerve agents soman and sarin.

Title: Training in Molecular and Mechanistic Toxicology

PI: Edson X. Albuquerque
Funding Agency: National Institutes of Health/National Institute of Environmental Health Sciences
Funding Period: 7/1/06 – 6/30/11

This is a training grant in toxicology that supports four predoctoral and two postdoctoral fellows for training in molecular and cellular toxicology.

Title: “Age and Sex Effects on Nerve Agent Damage to the Brain and Antidotal Therapies”

PI: Edson X. Albuquerque
Funding Agency: National Institutes of Health/National Institute of Neurological Disorders and Stroke
Funding Period: 5/1/06 – 4/30/11

In this research grant, a multidisciplinary approach will be used to study the effectiveness of a galantamine-based antidotal therapy against immediate and delayed toxic effects of nerve agents in male and female guinea pigs at different ages and in developing guinea pigs.

Title: “Novel Treatment of Menopausal Hot Flushes with Paraquinol of Estrogen”

PI: Istvan Merchenthaler
Funding Agency: National Institute of Aging, National Institutes of Health
Funding Period: 9/1/07 – 8/31/12

This research grant is aimed at evaluating a pro-drug approach to treat menopausal hot flushes utilizing animal models of hot flush. Paraquinol of estradiol, an inert compound, is converted to estradiol only in the central nervous system by a reductase. Since such conversion does not take place in the periphery, including the uterus, breast and liver, the pro-drug approach of estrogen therapy will be a safe and efficacious treatment/prevention for not only hot flushes but other conditions, where estrogen has been shown to exhibit beneficial effects such as dementia, Alzheimer’s disease, stroke, etc.

Title: “Novel Treatment of Menopausal Hot Flushes with Paraquinol of Estrogen”

PI: Istvan Merchenthaler
Funding Agency: National Institute of Aging, National Institutes of Health
Funding Period: 1/3/09 – 28/2/13

This research grant is aimed at evaluating pro-estrogen (paraquinol of estradiol) in animal models of depression/anxiety and sleep disturbances. The hypoestrogenic status during the peri-menopause and menopause is associated with increased incidence of depression and anxiety and sleep disorders. Since the pro-estrogen is converted to estradiol only in the brain, the pro-drug approach seems to be a safe and efficacious estrogen replacement therapy without any side effects in the periphery.

Title: “Fertamax to Prevent Egg Infertility”

PI: Istvan Merchenthaler
Funding Agency: Maryland Industrial Partnerships (MIPS)
Funding Period: 8/1/3/10 – 7/31/11

This research grant is aimed at evaluating the effects of elevated gonadotropin levels on chromosome structure and function. Our hypothesis is that elevated gonadotropin levels associated with a decline in estrogen production by the ovaries during the last years of reproductive years play a critical role in chromosomal aneuploidy and subsequent birth defects.

Title: “Maryland Organized Research Effort in Women’s Health (MORE-WH)”

PI: Pat Langenberg
Director: Istvan Merchenthaler
Funding Agency: National Institute of Health, Office of Research in Womens’ Health
Funding Period: 9/1/07 – 8/31/12

This training grant will provide interdisciplinary mentored training in women’s health research to junior faculty scholars in an effort to foster the expansion of women’s health research across a variety of disciplines.